financetom
SUGP
financetom
/
Industrials
/
SUGP
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
SU Group Holdings LimitedSUGP
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
Market Cap
9.87M
Revenue (ttm)
23.45M
Net Income (ttm)
1.37M
Shares Out
13.85M
EPS (ttm)
0.11
PE Ratio
6.65
Forward PE
n/a
Dividend
n/a
Ex-Dividend Date
n/a
Volume
34,947
Open
0.6530
Previous Close
0.6999
Day's Range
0.6501 - 0.7125
52-Week Range
0.5390 - 3.2900
Beta
n/a
Analysts
n/a
Price Target
n/a
Earnings Date
Apr 21, 2025
Description >

SU Group Holdings, through its subsidiaries, Shine Union and Fortune Jet, is an integrated security-related services company that primarily provides security-related engineering services, and to a lesser extent, security guarding and screening services and related vocational training services, in Hong Kong.

Shine Union has been providing turnkey services to the existing infrastructure or planned development of its customers through the design, supply, installation, and maintenance of security systems for over two decades.

The security systems that Shine Union provides services to include threat detection systems, traffic and pedestrian control systems, and extra-low voltage systems in private and public sectors, including commercial properties, public facilities, and residential properties in Hong Kong.

Shine Union is one of the few providers in the security-related engineering services market authorized to distribute over 10 brands of security systems.

Shine Union is also the exclusive distributor to market and sell two brands of threat detection systems, which include X-ray machines, trace detection products, metal detectors and mail screening machines.

Since our acquisition of Fortune Jet in 2019, we have also been providing security guarding and screening services and related vocational training services in Hong Kong.

Latest News >
Guardant Health Shares Halted; FDA Panel to Review Premarket Application of Colorectal Cancer Screening Test
Guardant Health Shares Halted; FDA Panel to Review Premarket Application of Colorectal Cancer Screening Test
May 23, 2024
07:57 AM EDT, 05/23/2024 (MT Newswires) -- Guardant Health ( GH ) shares were temporarily halted on Thursday as a Food and Drug Administration panel prepared to meet to review the premarket approval application for the company's Shield blood test to screen for colorectal cancer. Advisory committees provide independent expert advice and non-binding recommendations to the FDA, the company said....
Update: Market Chatter: Google Chooses State in Southern India for Smartphone Production
Update: Market Chatter: Google Chooses State in Southern India for Smartphone Production
May 23, 2024
07:57 AM EDT, 05/23/2024 (MT Newswires) -- (Updates with additional details.) Alphabet's (GOOG) Google ( GOOG ) is planning to invest billions of dollars in India's southern state of Tamil Nadu to set up production of its Pixel phones, Bloomberg reported Thursday, citing unnamed people familiar with the matter. Tamil Nadu's Minister for Industries T.R.B. Rajaa and other senior officials...
Market Chatter: Goldman Sachs Gets First-Ever Saudi HQ License for Wall Street Bank
Market Chatter: Goldman Sachs Gets First-Ever Saudi HQ License for Wall Street Bank
May 23, 2024
07:56 AM EDT, 05/23/2024 (MT Newswires) -- Goldman Sachs Group ( GS ) became the first Wall Street bank to receive a license from Saudi Arabia to set up its regional headquarters in Riyadh, Bloomberg reported Thursday, citing people familiar with the matter. Under state contract rules issued in 2021 that went into effect this year, firms must have a...
Tango Therapeutics Discontinues TNG348 Program After Showing Liver Toxicity in Trials; Shares Tumble Premarket
Tango Therapeutics Discontinues TNG348 Program After Showing Liver Toxicity in Trials; Shares Tumble Premarket
May 23, 2024
07:55 AM EDT, 05/23/2024 (MT Newswires) -- Tango Therapeutics ( TNGX ) said Thursday it will discontinue developing its TNG348 program due to liver toxicity experienced by patients during clinical trials. Patients remaining in the study for more than eight weeks exhibited liver function abnormalities, leading to the decision to terminate the program, Tango said. TNG348 was being developed as...
Copyright 2023-2025 - www.financetom.com All Rights Reserved